Loading people...
Jason Rhodes is a Partner at Atlas Venture in Cambridge, Massachusetts, focusing on creating early-stage biotechnology companies. Previously, he served as President and Chief Financial Officer of Epizyme, guiding the firm through its 2013 initial public offering, and was Vice President of Business Development at Alnylam Pharmaceuticals. Rhodes has held founding Chief Executive Officer and chairman roles at multiple therapeutics firms, including Dyne Therapeutics and Generation Bio, guiding both through respective $233 million and $230 million IPOs in 2020. His venture portfolio includes notable exits like the acquisition of Disarm Therapeutics by Eli Lilly and the sale of FoldRx to Pfizer during his tenure at Fidelity Biosciences. Holding degrees from Yale University and the Wharton School, Rhodes leverages his operational and financial expertise to build novel life sciences startups from inception through the public markets.
Jason Rhodes is a distinguished Partner at Atlas Venture, a leading venture capital firm renowned for its impactful investments in the life sciences sector. At Atlas Venture, Jason plays a pivotal role in the firm's unique venture creation model, focusing intensely on the inception, development, and financing of innovative therapeutics companies. His work is primarily centered on identifying and nurturing groundbreaking scientific discoveries that have the potential to transform patient care.
His investment focus areas are deeply rooted in biotechnology, encompassing novel drug discovery, therapeutic development, and the creation of platforms that address significant unmet medical needs. Jason is known for his hands-on approach, often co-founding companies and serving on their boards from their earliest stages, guiding them through critical phases of growth and scientific advancement. This commitment to company building from the ground up is a hallmark of his strategy at Atlas Venture.
Before joining Atlas Venture in 2007, Jason Rhodes had already established a strong foundation in the biotech industry. He was a co-founder and Vice President of Business Development at Alnylam Pharmaceuticals, a pioneering company in RNA interference therapeutics. His experience at Alnylam provided him with invaluable insights into the challenges and opportunities of translating cutting-edge science into viable therapeutic products. Prior to Alnylam, he honed his strategic and analytical skills as a consultant at Monitor Group. Jason holds an MBA from Harvard Business School and a BA from Bowdoin College, providing him with a robust blend of scientific understanding and business acumen.
Throughout his career at Atlas Venture, Jason Rhodes has been instrumental in the creation and success of numerous notable biotechnology companies. His portfolio includes a diverse range of ventures that have gone on to make significant strides in their respective fields. Key companies he has co-founded or played a crucial role in include Generation Bio, Synlogic, Kodiak Sciences, Disc Medicine, Vedanta Biosciences, Dyne Therapeutics, and Accent Therapeutics. These companies exemplify his dedication to fostering innovation and bringing transformative medicines to patients. Jason Rhodes continues to be a driving force in the biotech investment landscape, consistently seeking out and building the next generation of life science leaders.
Jason Rhodes is a Partner at Atlas Venture, a prominent venture capital firm. He is known for his work in founding and investing in novel therapeutics companies within the biotechnology sector.
Jason Rhodes invests in early-stage biotechnology companies focused on novel therapeutics, drug discovery, and development. He often plays a key role in the creation and incubation of these ventures from inception.
Jason Rhodes works as a Partner at Atlas Venture, a leading venture capital firm with offices in Cambridge, Massachusetts, specializing in life sciences investments.
